First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Terminated · Phase 1, Phase 2 · NCT03110107
Conditions: Advanced Cancer
At a glance
- Research payments reported, 2025
- $2,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 376
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Ipilimumab (biological), BMS-986218 (biological), Nivolumab (biological)
- Dates
- Started 2017-05-04; completion 2024-04-04
- Results posted
- Yes
The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.
From ClinicalTrials.gov, last updated 2025-04-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $2,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.